Company intelligence / Profile preview
Gwo Xi Stem Cell Applied Technology Co., Ltd.
- Ownership
- Private
- Development stage
- Phase 2
Overview
Gwo Xi has several ongoing clinical trials for autologous and allogeneic adipose-derived stem cell therapies targeting liver cirrhosis, chronic stroke, osteoarthritis, and diabetes. One program has completed Phase I/II trials; others are in Phase II or I/II. Early results suggest safety and potential efficacy for unmet medical needs.[5][10]
- Therapeutic areas
- GastroenterologyEndocrinologyNeurologyRheumatology
- Modalities
- Autologous adipose-derived stem cell therapyAllogeneic adipose-derived stem cell therapyMesenchymal stem cell therapy[2][3]
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Gwo Xi Stem Cell Applied Technology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gwo Xi Stem Cell Applied Technology Co., Ltd..